.cls-1{fill:#f55014;}.cls-2{fill:#776e64;} Hem>Investors>The share>Share capital development Share capital development Share this: The share capital development Year Event Total share capital (SEK) Change (SEK) Total number of shares Difference in shares Amount issued (SEK) Ratio value (SEK) 2013 Formation 50 000 50 000 100 000 100 000 25 000 000 0.50 2015 Rights issue 84 473 34 473 168 946 68 946 24 106 969 0.50 2015 Rights issue 104 169 16 696 208 338 39 392 14 772 000 0.50 2015 Rights issue 115 379 11 210 230 757 22 419 8 047 125 0.50 2015 Share subdivision 115 379 2 307 570 2 076 813 0.05 2015 Cash issue 181 358 65 980 3 627 162 1 319 592 54 515 644 0.05 2016 Rights issue 231 358 50 000 4 627 162 1 000 000 41 350 000 0.05 2016 Rights issue 249 919 18 561 4 998 388 371 226 15 350 195 0.05 2016 Rights issue 253 497 3 578 5 069 939 71 551 726 243 0.05 2016 Stock dividend issue 596 994 253 497 5 069 939 0 0 2017 Rights issue 699 994 193 000 6 999 939 1 930 000 115 800 000 0.10 2018 Rights issue 809 994 110 000 8 099 939 1 100 000 138 600 000 0.10 2019 Share split 1:5 809 994 0 40 499 695 32 399 756 0 0.02 2019 Rights issue 862 194 52 200 43 109 695 2 610 000 70 470 000 0.02 2020 Rights issue 969 968 107 774 48 498 406 5 388 711 145 495 197 0.02 2020 Rights issue 1 034 968 65 000 51 748 406 3 250 000 130 000 000 0.02 At end of period 1 034 968 51 748 406 784 233 373 0.02 Issued amount is total issued amount incl. share premium but before issue costs. IRLAB Therapeutics AB (publ) Arvid Wallgrens Backe 20 413 46 Göteborg +46 31 757 38 00 Copyright © 2021 IRLAB Integrity policy

.cls-1{fill:#f55014;}.cls-2{fill:#776e64;} Hem>Investors Investors Share this: IRLAB A ____ > Interim report Q2 2021 > Annual report 2020 > Latest presentation Earnings call Q3 November 10, 2021 Telco in connection with publication of quarterly report for the thrid quarter 2021 The presentation is available here (held in Swedish): https://tv.streamfabriken.com/irlab-q3-2021 To download the presentation as a pdf (in English), click here: IRLAB Q3 2021 presentation For more information Åsa Hillsten, Head of IR & Corporate Communications Telephone: +46 700 81 81 17 E-mail: […] Read More > Presention at ProHearings by Nicholas Waters, CEO (Swedish) August 25, 2021 Read More > CEO Nicholas Waters, CEO, participated at Redeye Growth Day 2021 June 2, 2021 Nicholas Waters, CEO, presented at Redeye Growth Day on June 2, 2021. The presentationen is followed by a Q&A and is held in English. Watch here > Read More > All presentations & events > All press releases > Subscribe Coming events February 23, 2022 Year-end Report, 2021 IR contact Viktor Siewertz, CFO viktor.siewertz@irlab.se +46(0)72 710 70 70 IRLAB Therapeutics AB (publ) Arvid Wallgrens Backe 20 413 46 Göteborg +46 31 757 38 00 Copyright © 2021 IRLAB Integrity policy